$MDGL News

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach

Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade)

Madrigal Pharmaceuticals Q2 Earnings Call Highlights

Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Q2 Beat Yet Shares Slide on Rezdiffra Ramp Worries

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate

Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685